Prenetics Announces Tencent's US$30 Million Investment in Insighta, Strengthening Strategic Partnership for AI-Driven Early Cancer Detection
HONG KONG, Oct. 15, 2024 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced thatTencent has made a strategicUS$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta atUS$200 mill...
Prenetics Announces Second Quarter 2024 Financial Results
Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024 Enters U.S. Health Market in October with IM8, a New Health and Wellness brand Re-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 7, 2024 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Preneti...
Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry
Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C...
Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham
* Beckham becomes a strategic investor in Prenetics * Beckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 /PRNewswire/ -- Prenetics, (NASDAQ: PRE) a leading health sciences company, is proud to announce that former international...
Prenetics Announces First Quarter 2024 Financial Results
First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 /PRNewswire/ -- Prenetics Global Limit...
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
HONG KONG, April 1, 2024 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year endedDecember 31, 2023, along with recent business up...
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
* Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in space * Dr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory Board ...
Prenetics Announces Third Quarter 2023 Financial Results
HONG KONG, Nov. 20, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter endedSeptember 30, 2023, along with recent business updates. Third Quarter 20...
Prenetics Announces Second Quarter 2023 Financial Results
HONG KONG, Sept. 15, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the second quarter endedJune 30, 2023, along with recent business updates. Second Quarter 2023...
A World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television
* Miss Hong Kong Pageant 2023 winner is Hilary Chong (no. 15) HONG KONG, Aug. 29, 2023 /PRNewswire/ -- In a move that had never been seen before, marrying beauty with science, the Miss Hong Kong Pageant 2023, which justaired on TVB, had set out to revolutionize the industry by partnering with C...
Prenetics Announces First Quarter 2023 Financial Results
HONG KONG, June 5, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the first quarter endedMarch 31, 2023, along with recent business updates. First Quarter 2023 Fi...
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
New Business Strategy Focused on Precision Oncology LONDON and HONG KONG, March 14, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full yea...
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
LONDON and HONG KONG, March 2, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and c...
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
LONDON and HONG KONG, Jan. 19, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commi...
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a c...
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
* Revenue of US$51.7 million in the second quarter of 2022 * Loss from operations of US$(17.9) million and adjusted EBITDA[1] of US$6.5 million in the same period * Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue ...
Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device
- Circle Snapshot, a patented, painless, at-home blood test with laboratory results delivered digitally. - The test utilises a CE-certified blood collection device, which is a proprietary micro-needle technology that draws capillary blood painlessly using a novel microfluidic extraction process....
Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong
- Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies - ColoClear is the onl...
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE"
LONDON and HONG KONG, June 6, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. The Company recorded strong opera...
